Last reviewed · How we verify
Sonu Nasal Congestion Relief Study in Patients Suffering From Moderate to Severe Nasal Congestion
NA trial testing Sonu in Nasal Congestion and Inflammations in 52 participants. Completed in 30 June 2023.
| Lead sponsor | Third Wave Therapeutics |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 52 |
| Start date | 23 March 2022 |
| Primary completion | 30 April 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across United States |
Third Wave Therapeutics
18 and older, any sex, with Nasal Congestion and Inflammations. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in nasal congestion sub-score compared to baseline. The nasal congestion sub-score is reported on a scale of 0-3. 0 is the minimum and 3 is the maximum. Higher scores mean worse outcomes.
| Group | Value | 95% CI |
|---|---|---|
| Sonu Treatment Group | -0.87 | -1.11 – -0.62 |
| Sham Control Group | -0.44 | -0.64 – -0.23 |
Change in total nasal symptom score (TNSS) compared to baseline. The TNSS is the sum of four (4) symptom sub-scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each self-rated by the subject using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. TNSS scores are reported on a scale of 0-12. 0 is the minimum and 12 is the maximum. Higher scores mean worse outcomes.
| Group | Value | 95% CI |
|---|---|---|
| Sonu Treatment Group | -2.85 | -3.85 – -1.85 |
| Sham Control Group | -1.32 | -2.27 – -0.36 |
To demonstrate the safety and effectiveness of Sonu for the treatment of patients suffering from moderate to severe nasal congestion.
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05821842.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing